

Article

Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90

Alex Henke ^{1,†}, Omar E. Franco ^{2,‡}, Grant D. Stewart ^{3,§}, Antony C.P. Riddick ^{3,§}, Elad Katz ^{4,||}, Simon W. Hayward ^{2,‡} and Axel A. Thomson ^{5,*}

¹ Medical Research Council, Centre for Reproductive Health, The Queens's Medical Research Institute, Edinburgh EH16 4TJ, UK; dr.a.henke@gmail.com

² Department of Urologic Surgery and Cancer Biology, Vanderbilt University, Nashville, TN 37232-2765, USA; ofrancocoronel@northshore.org (O.E.F.); SHayward@northshore.org (S.W.H.)

³ Edinburgh Urological Cancer Group, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK; grant.stewart@ed.ac.uk (G.D.S.); ariddick@doctors.org.uk (A.C.P.R.)

⁴ Division of Pathology, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK; e.katz@dundee.ac.uk

⁵ Division of Urology, Department of Surgery, Cancer Research Program, McGill University Health Centre Research Institute, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada

* Correspondence: axel.thomson@mcgill.ca; Tel.: +1-514-934-1934 (ext. 76307)

† Current address: Shire, Edisonstr. 2, 85716 Unterschleissheim, Germany.

‡ Current address: Department of Surgery, NorthShore University HealthSystem Research Institute, 1001 University Place, Evanston, IL 60201, USA.

§ Current address: Academic Urology Group, University of Cambridge, Box 43 Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

|| Current address: University of Dundee, Dow Street, Dundee DD1 5EH, UK.

Academic Editor: Huey-Jen Lin

Received: 21 December 2015; Accepted: 3 August 2016; Published: 24 August 2016

Abstract: *Background:* Prostate cancer-associated fibroblasts (CAF) can stimulate malignant progression and invasion of prostatic tumour cells via several mechanisms including those active in extracellular matrix; *Methods:* We isolated CAF from prostate cancer patients of Gleason Score 6–10 and confirmed their cancer-promoting activity using an in vivo tumour reconstitution assay comprised of CAF and BPH1 cells. We tested the effects of heat shock protein 90 (HSP90) inhibitors upon reconstituted tumour growth in vivo. Additionally, CAF contractility was measured in a 3D collagen contraction assay and migration was measured by scratch assay; *Results:* HSP90 inhibitors dipalmitoyl-radicicol and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) reduced tumour size and proliferation in CAF/BPH1 reconstituted tumours in vivo. We observed that the most contractile CAF were derived from patients with lower Gleason Score and of younger age compared with the least contractile CAF. HSP90 inhibitors radicicol and 17-DMAG inhibited contractility and reduced the migration of CAF in scratch assays. Intracellular levels of HSP70 and HSP90 were upregulated upon treatment with HSP90 inhibitors. Inhibition of HSP90 also led to a specific increase in transforming growth factor beta 2 (TGFβ2) levels in CAF; *Conclusions:* We suggest that HSP90 inhibitors act not only upon tumour cells, but also on CAF in the tumour microenvironment.

Keywords: prostate cancer; cancer associated fibroblast; heat shock protein; contractility

1. Introduction

Carcinomas are complex multi-cellular communities, consisting of tumour epithelia, immune cells, stroma, and the surrounding microenvironment. The relationships between these tissues evolves as the tumour progresses from a localized well differentiated lesion to an invasive and less organized structure. In recent years the tumour microenvironment (TME) has become increasingly recognized as an active and functionally important regulator of tumour progression and response to treatment. The TME includes many cell types including fibroblasts, nerves, endothelial cells and pericytes and immune/inflammatory cells, as well as components of the organ-specific stroma such as smooth muscle and adipocytes. Cancer-associated fibroblasts (CAF) were identified as active, pro-tumourigenic key players in the stroma, as they can promote malignant progression in initiated but non-tumourigenic epithelial cells [1]. CAF communicate with, and regulate the proliferation, of adjacent epithelia via multiple signalling molecules, e.g., CXCL12 and TGF β [2–4]. They can also modulate the local extracellular matrix by secretion of matrix metalloproteinases (MMP) and deposition of hyaluron and collagen [5], thereby stiffening the tissue. The increased tissue stiffness in itself may act as a tumour-promoting, physical cue during tumour progression [6]. CAF can create paths for tissue invasion of epithelial cells [7,8], which requires contractility and motility [7–9]. Inhibition of CAF contractility or motility is a potential therapeutic target.

The TME and CAF are targets for a variety of approaches to inhibit tumour growth, though at present few are sufficiently potent to be primary treatments [10]. Cancer cells show considerable genetic instability, allowing them to evolve mechanisms to escape therapy leading to eventual disease relapse. In contrast, cells of the TME appear to be genetically stable [11] although there may be epigenetic changes in CAF. Hence, drugs targeting the TME may be less subject to development of resistance compared to tumour cell targeted therapies. Drugs targeting TME could be indirect anti-tumour agents that might work in conjunction with conventional agents, a recognition that has already led to some development and clinical testing [12].

HSP90 is a highly abundant and ubiquitously expressed protein with involvement in many cellular processes. Although HSP90 is not a conventional target for cancer therapy, several inhibitors have been developed some of which are being tested in clinical trials [13,14]. HSP90 inhibitors may target directly the tumour cells to inhibit motility and invasion [15], or by indirect effects via angiogenesis [16,17]. There is also evidence for effects of HSP90 inhibitors upon fibroblast migration and fibrosis [18,19] as well as direct inhibition of CAF tumour interactions [20]. Other studies demonstrated secretion of extracellular HSP90 by prostate tumour cells to stimulate the conversion of fibroblasts into CAF [21,22]. These studies illustrate that HSP90 inhibition may have effects upon several aspects of tumour growth; both direct as well as indirect.

In this study we tested the HSP90 antagonists radicicol and 17-DMAG upon CAF-induced tumour growth, and observed inhibition of tumour size and proliferation. We used a 3D collagen contraction assay to examine CAF from patients of different ages and pathological features and tested the effects of HSP90 inhibitors in this assay. HSP90 inhibition led to a reduction in collagen contractility and reduced CAF migration. We suggest that some effects of HSP90 inhibition upon tumour growth in vivo may be mediated via CAF, in addition to direct effects previously documented upon tumour cells.

2. Results

2.1. CAF Isolation

Tissue from patients undergoing transurethral resection of the prostate (TURP) with a prior cancer diagnosis were used for CAF isolation. We isolated prostatic CAF from TURP samples and grew 20 PCa CAF cultures from 40 patients with a Gleason Score of six or higher, or poorly differentiated carcinoma. Routine pathology on biopsies before surgery and on TURP samples after surgery confirmed the presence of PCa. Supplementary Table S1 gives an overview of patients from whom CAF were derived. Microseminoprotein (MSMB) beta is a protein expressed in normal and BPH prostate but is decreased

or absent in PCa [23], and we stained patient samples for MSMB to confirm the presence of tumour in the tissue specimens. While BPH control tissue showed strong MSMB staining, this was low or absent in PCa specimens, as shown in Figure 1A.




Figure 1. Characterisation of cancer-associated fibroblasts (CAF) and inhibition of tumour size and proliferation after treatment with HSP90 inhibitors. (A) Immunohistochemistry for Microseminoprotein (MSMB) showed positive staining in non-malignant benign prostatic hyperplasia BPH tissue (left panel; inset: antibody control) but was mostly absent in PCa (right panel) and was used to confirm tumour presence in tissue from which CAF were derived. Microscopy with 10× objective lens; PCa panel has identical scale as images in (B) (scale bar 200 μM). BPH images also with 10× objective lens but illustration at half the size as the other images in (A,B); (B) Collagen was stained by picrosirius red in BPH (non-malignant) and prostate cancer with a Gleason score of 9. Collagen was more abundant in prostate cancer samples. Microscopy with 10× objective; scale bar 200 μM; (C) Recombination of normal prostate fibroblasts (neg. ctrl., negative control) with BPH1 cells and kidney capsule grafting produced little growth (arrows). Recombination of previously validated CAF (pos. ctrl., positive control) and CAF isolates F and N with BPH1 cells led to tumour growth, demonstrating pro-tumorigenic activity of our primary CAF. Images in the upper row shows gross morphology, while the lower row shows cross sections of tumours used for size measurements; (D) CAF/BPH1 tumours were grown for 2 months followed by a 1 month treatment with vehicle control (veh), dipalmitoyl-radicalol (DPR) at 50, 100 and 200 mg/kg or with 17-DMAG (DMAG) at 5, 10 and 20 mg/kg. Tumour size was reduced after treatment with dipalmitoyl-radicalol at all doses, and with DMAG at 10 or 20 mg/kg. The vehicle control group was the same for both treatment groups since tests were performed simultaneous in parallel. Data are presented as mean + S.E.M. and asterisks denote the level of significance * for $p < 0.05$, ** for $p < 0.01$ and *** for $p < 0.001$. n.s. = not significant. Statistical test: one-way ANOVA. Individual data are provided in Supplementary Table S2; (E) To examine effects upon cell proliferation within

tumours, tissue sections of CAF/BPH1 tumours were stained for the proliferation marker Ki67, and positive nuclei counted. The highest doses of DPR treatment (200 mg/kg) and DMAG treatment (20 mg/kg) resulted in a significantly decreased Ki67 index. $n = 3$; one way-ANOVA, data are presented as mean + S.E.M. and asterisks denote the level of significance as mentioned above.

Cellular heterogeneity of CAF populations is well documented *in vivo* and *in vitro* [4,24–26]. Some organs, such as breast, contain few myofibroblasts, and hence an increase of the proteins alpha smooth actin (α SMA) and vimentin (VIM) is considered to be a marker of CAF in these tissues. In the prostate, smooth muscle cells are abundant and therefore α SMA is not a reliable CAF marker [27]. However, reactive stroma can be identified by picrosirius red staining [28–30], which detects collagen deposition. Picrosirius red staining of our samples of BPH and PCa samples are shown in Figure 1B, and PCa tissue showed extensive collagen-positive areas while these were absent or less extensive in BPH tissue. A previous publication from our laboratory demonstrated expression of VIM, SMACT (Smooth Muscle Alpha Actin), FSP (Fibroblast Specific Protein) and smooth muscle marker CNN (Calponin) in CAFs [24].

We used an *in vivo* xenograft assay to demonstrate tumour-promoting properties of our CAF. CAF from 11 patients were recombined with non-tumourigenic but initiated prostatic epithelial cells (BPH1), encased in a collagen matrix, and grafted under the kidney capsule of immune-deficient SCID mice. After three months, kidneys and grafts were explanted and tumour size measured, and volume estimated using an ellipsoid formula [1]. All CAF populations initiated tumour growth in BPH1 cells. Control normal primary fibroblasts (Figure 1C), which were obtained from a histological normal region from a patient with prostate cancer, who underwent radical prostatectomy, did not form tumours. Hence, in this bioassay we demonstrated that the fibroblast populations showed pro-tumourigenic CAF-activity, consistent with previously published studies [1].

2.2. The Effects of HSP90 Inhibitors upon CAF-Induced Tumourigenesis *in Vivo*

Our interest in HSP90 emerged from studies where we used small molecule inhibitors of signalling pathways *in vitro*, and observed a significant effect of inhibitors with documented “off target” effects upon HSP signaling. This led us to try HSP90 inhibitors directly. We studied the effects of HSP90 inhibitors upon tumours reconstituted from CAF and BPH1 cells which were allowed to develop for 2 months prior to the start of treatment with HSP90 inhibitors. This is a translationally relevant model of patient tumours that might undergo treatment with HSP90 inhibitors. We chose to assay the effects of 14,16-dipalmitoyl-radicicol and 17-DMAG which are structurally independent HSP90 inhibitors. Radicicol was reported to be ineffective *in vivo*, but a lipidated derivative, 14,16-dipalmitoylradicicol, showed anti-tumour activity *in vitro* and *in vivo* [31]. In order to exclude possible off-target effects and confirm the findings with dipalmitoyl-radicicol, we also used 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an HSP90 inhibitor that is structurally unrelated to radicicol. At the time when this study was initiated, other HSP90 inhibitors such as AUY922 or ganetisib were not available and these newer inhibitors show better efficacy. Two CAF populations were used to generate CAF/BPH1 recombinants and xenografted into SCID mice with three grafts per kidney. The tumours were grown for two months before the start of *i.p.* injections every four days over one month with 0, 50, 100 and 200 mg/kg dipalmitoyl-radicicol or 0, 5, 10 and 20 mg/kg 17-DMAG. Despite sample heterogeneity, the HSP90 inhibitor-treated animals had significantly lower tumour volumes than the vehicle control-treated animals (Figure 1D). One animal in the group receiving the highest dose of dipalmitoyl-radicicol died due to unknown causes. HSP90 inhibitors have been shown to cause liver toxicity in an animal model of gastrointestinal cancer [32] and also in patients with castration-resistant prostate cancer in a phase II clinical trial for a novel HSP90 inhibitor [33]. Nevertheless, the reduction in tumour size using dipalmitoyl-radicicol was statistically

significant at 100 mg/kg, while 17-DMAG at either 10 or 20 mg/kg elicited a significant reduction in tumour size.

Next, we examined effects of treatment with HSP90 inhibitors upon cellular proliferation using nuclear Ki67 expression in tissue sections of xenografts after treatment. Histology of the tumours is shown in Supplementary Figure S1. We observed a dose-dependent reduction in Ki67 staining after treatment of tumours with dipalmitoyl-radicicol and 17-DMAG (Figure 1E). Quantitative analysis demonstrated a substantial reduction in Ki67-positive nuclei from 58% in the control group to 3.6% in the highest dose dipalmitoyl-radicicol treatment group and 0.8% in the 17-DMAG group ($p = 0.0079$ and $p = 0.0010$, respectively; one-way ANOVA) (Figure 1D). Taken together, the effects upon tumour size and cellular proliferation indicated that inhibition of HSP90 reduced tumour cell growth, albeit with a potential narrow therapeutic dosage window. 17-DMAG appeared to be better tolerated than di-palmitoyl-radicicol *in vivo*.

2.3. Effects of HSP90 Inhibitors Upon CAF Contractility *in Vitro*

We examined the ability of CAF to contract collagen gels in a 3D assay, and examined patient characteristics as well as effects of HSP90 inhibitors. We modified the assay to improve reproducibility by complete dislodgement of gels from bottom and walls of the wells and brief temporary removal of medium for imaging and subsequent quantitation. Figure 2A shows contraction of a collagen gel over 24 and 48 h. Contractility in a 3D collagen lattice was observed for CAF, but not for embryonic prostate fibroblasts or fibroblast cell lines (Figure 2B). Prostatic CAF reduced the gel area to an average of 59% (SD = 10.3%) of the original size after 48 h ($n = 20$ CAF isolates), while primary human embryonic prostatic fibroblasts (HEPF) had only minimal contractility ($n = 4$ samples). Also the NIH3T3 fibroblast cell line and the human prostatic myofibroblast cell line WPMY-1 (Figure 2B) showed little contractility. We demonstrated that CAF had a significantly enhanced contractility compared to other fibroblasts (CAF vs. HEPF $p < 0.0001$, and CAF vs. cell lines $p = 0.0002$).




Figure 2. Contractility of CAF *in vitro* and comparison with Gleason grade and age. (A) Top: schematic diagram illustrating the collagen gel contraction (CGC) assay. Fibroblasts were embedded into a collagen matrix (grey) which contracted during culture period followed by measurement and

calculation of percentage contraction; Bottom: images of a collagen gel at 0, 24 and 48 h showing a 68%–57% reduction in size; this corresponds to a contractility of 0%, 32% and 43%; (B) Comparison of collagen contractility of CAF with human embryonic fibroblasts and fibroblast cell lines after 48 h. CAF ($n = 20$ different primary lines) contracted collagen gels while human embryonic prostatic fibroblasts (HEPF) ($n = 4$ different primary lines) and fibroblast cell lines (NIH3T3 & WPMY-1; $n = 2$) showed significantly less contractility ($p < 0.0001$ and $p = 0.0002$, respectively; unpaired, two-tailed t -test); (C) Comparison of contractility with Gleason score, when comparing most and least contractile quartiles. The highest contractility was demonstrated by CAF lines from patients with a significantly lower Gleason score than in CAF lines from patients with the lowest contractility rate and highest Gleason score (48 h of incubation, $n = 4$ per group, two-tailed Mann Whitney test, $p = 0.036$); (D) The age of donors was significantly lower in the most versus the least contractile CAF lines (48 h of incubation, $n = 5$ per group; unpaired, two-tailed t -test, $p = 0.046$). (B–D) Data are presented as mean + S.E.M. and asterisks denote the level of significance: * for $p < 0.05$, ** for $p < 0.01$ and *** for $p < 0.001$.

2.4. CAF Contractility and Patient Parameters

We examined potential correlations between patient clinical parameters and CAF contractility. We observed no significant correlation of contractility of our CAF ($n = 20$ lines) with Gleason Score or age, possibly due to low sample number, though there appeared to be a modest trend (Supplementary Figure S2). Thus, we re-examined the extreme cases of contractility of the upper and lower quartiles. Two CAF isolates were from poorly differentiated PCa, and since the patients were receiving hormone treatment they were not assigned a Gleason score. This reduced the number of CAF to four for each contractility group of the most versus the least contractile CAF. The least contractile CAF were derived from patients with significantly higher Gleason Score than the most contractile CAF isolated from patients with lower Gleason scores (Figure 2C). When the three most and three least contractile CAF lines were xenografted with BPH-1 cells into mice, the highly contractile CAF produced larger tumours than the less contractile CAF but this difference was not statistically significant, possibly due to high intra-group variability (Supplementary Figure S3). When age and CAF contractility were compared, CAF from younger patients exhibited lower contractility than older patients (Figure 2D).

2.5. Analysis of HSP Inhibitors upon Contractility and Potential Cytotoxicity

We determined the effects of radicicol and 17-DMAG upon CAF contractility in the 3D collagen gel contraction (CGC) assay. To ensure that effects were not due to cellular toxicity of the HSP90 inhibitors, we used a sensitive colorimetric assay of viable cells within the collagen gels, based on the NAD(P)H-dependent reaction of dehydrogenase enzymes that converts a tetrazolium salt (MTS) into formazan. We identified radicicol as a potent inhibitor of CAF contractility in the 200–300 nanomolar range (Figure 3A). We observed little or no cytotoxicity of radicicol in the MTS assay (Figure 3B). This suggests that radicicol treatment had a direct effect upon contractility rather than indirect effects via cell toxicity. We repeated our analysis with 17-DMAG, which significantly impeded CAF contractility without cytotoxic effects in a dose-responsive fashion at nanomolar concentrations (Figure 3C,D), though the highest dose led to some cell toxicity. In addition, we used dorsomorphin (also known as compound C), which showed significant inhibition of contractility (Supplementary Figure S4). Dorsomorphin has been reported to inhibit both BMP signalling as well as HSP90 and other off-target effects [34]. We suggest that the effect upon contractility was via HSP90 effects rather than via BMP inhibition, as the use of another, specific BMP inhibitor (LDN-193189) did not affect contractility in our experiments. Taken together, the inhibitors targeting HSP90 showed significant effects upon CAF contractility.

2.6. Effects of HSP90 Inhibitors upon Motility

The effect of HSP90 inhibitors was also tested in a wound closure (WC, scratch) assay to address effects upon CAF motility. The open area of scratches *in vitro* was quantified with ImageJ directly after scratch initiation ($t = 0$ h) and after 24 h of culture with or without HSP90 inhibitors. Both, radicicol and

17-DMAG, significantly reduced the migration of CAF into the scratch area in comparison with controls ($p = 0.0048$ and 0.0036 , respectively) (Figure 3E,F). We conclude that HSP90 inhibition significantly impaired the motility of CAF.




Figure 3. Effects of HSP90 inhibitors upon CAF contractility and mobility. (A) Radicicol inhibited collagen gel contraction (CGC) by CAF in a dose-dependent manner ($p < 0.001$ for all doses and time points vs. vehicle control; $n = 21$ experiments in triplicates for 0 nM, $n = 18$ for 100 nM and $n = 16$ for 300 nM with a total of 11 different CAF lines; unpaired two-sided t -test); (B) Treatment with radicicol did not reduce cell viability, as measured with an MTS assay after the CGC ($n = 10$ independent experiments and CAF lines; repeated measures ANOVA, $p > 0.05$; not significant). NT = no treatment; 0 nM received the dose of vehicle comparable to the highest treatment dose; (C) 17-DMAG significantly inhibited collagen gel contraction in a dose-dependent manner ($n = 3$ CAF lines and independent experiments in triplicates; repeated measures ANOVA, $p < 0.001$ for all doses); (D) 17-DMAG showed little effect upon cell viability in an MTS assay of CAF after the CGC except for the highest dose of 60 nM ($n = 3$ independent experiments and CAF lines; repeated measures ANOVA, $p < 0.01$); (E) Radicicol treatment (300 nM) reduced CAF migration in wound closure (WC) in the scratch assay after 24 h. $n = 5$ CAF populations, paired, two-sided t -test. NT = no treatment; (F) 30 nM 17-DMAG reduced migration in the scratch assay in CAF after 24 h. $n = 5$ CAF populations, $p < 0.01$ paired, two-sided t -test. All panels: mean + S.E.M. and asterisks denote the level of significance: * for $p < 0.05$, ** for $p < 0.01$ and *** for $p < 0.001$. Incubation times: CGC 48 h, MTS 3 h, WC 24 h.

2.7. HSP90 Inhibitors and Secretion of TGF β

CAF overexpress many chemokines and growth factors including transforming growth factor beta (TGF β). TGF β has cell compartment-specific autocrine and paracrine effects, it contributes to

tumour cell proliferation by up-regulating CXCR4 in epithelial cells, and enhancing invasion [3,35]. It also regulates fibroblast and smooth muscle cell differentiation [27,36,37], which may be relevant to contractility by altering CAF differentiation and subsequent indirect effects upon contractility. The secretion of TGF β by CAF was measured in conditioned medium from CAF exposed to HSP90 inhibitors or vehicle control for 24 h, using a multiplex bead assay. While 17-DMAG had no effect, Radicicol led to a very small but significant down-regulation of TGF β 1 protein (Figure 4A). In contrast, the secretion of TGF β 2 protein was significantly up-regulated by 17-DMAG but not by radicol (Figure 4B). The levels of TGF β 3 were below detection limits in all cases. In summary, there was a compound-dependent and mixed effect on TGF β protein secretion by CAF exposed to HSP90 inhibitors. To determine whether the increase in TGF β secretion might be mediating some effects upon contractility, we added recombinant human TGF β 2 protein and TGF β -inhibiting antibodies to CAF in the CGC, however, these had no effect on contractility.




Figure 4. Multiplex bead assay to measure TGF β and HSP protein levels in CAF following HSP inhibitor treatment. CAF were treated with Radicicol or 17-DMAG and conditioned medium was assayed for secreted TGF β 1 (A) and TGF β 2 (B); TGF β 1 levels remained the same or were slightly decreased by radicol treatment, while TGF β 2 secretion increased upon treatment with 17-DMAG. Intracellular levels of HSP70 (C) and HSP90 AA1 (D) were measured in CAF cell lysates. Increased levels of both HSP70 and HSP90 AA1 were observed after treatment with both, 17-DMAG and radicol ($n = 4$ different CAF lines measured in duplicates; paired, one-sided t -tests). All panels: mean + S.E.M. and asterisks denote the level of significance as mentioned above.

2.8. HSP Levels Following Treatment with HSP90 Inhibitors

Next, we examined intracellular protein levels of heat shock proteins in CAF after treatment with HSP90 inhibitors. Lysates of treated CAF were subjected to a multiplex bead assay for HSP70, HSP90 AA1, HSP27 and HSP60. Both 17-DMAG and radicol led to a significant increase of HSP70 (Figure 4C) and HSP90 isoform AA1 in the cytosol of lysed CAF (Figure 4D). Radicicol had no significant impact on total or phosphorylated HSP27 or HSP60, but 17-DMAG treatment resulted in a decrease in phosphorylated HSP27 and an increase in HSP60 (Supplementary Figure S5). These data confirm that HSP90 inhibitors lead to increased intracellular levels of HSP70 and HSP90. Overexpression of HSPs

after treatment with small molecules inhibitors has been observed in other systems, consistent with our observations [15,17], and suggest that our inhibitors were eliciting effects in CAF.

2.9. Effects of HSP90 Inhibitors upon ROCK in Vitro

Recent studies have shown that CAF can create paths through the ECM (Extra Cellular Matrix) which tumour cells follow during invasion, and this process is dependent on CAF cellular contractility controlled by the Rho/ROCK pathway [8]. Therefore, we examined whether ROCK (Rho-associated protein kinase) inhibition via two structurally different inhibitors was also able to impair CAF contraction of gels directly, without cytotoxic effects. Y-27632 significantly decreased collagen gel contraction ($n = 3$ CAF lines; $p = 0.0041$; 1 way ANOVA) (Figure 5A) without cytotoxic effects as measured via the MTS assay, despite of high doses of 10 μ M (Figure 5B). A second, structurally unrelated compound, fasudil, also significantly reduced collagen gel contraction ($n = 3$ CAF lines; $p = 0.0256$; 1 way ANOVA) without cellular cytotoxicity (Figure 5C,D). However, when the inhibitors were used in the scratch assay, we found no inhibition of the motility of CAF (Figure 5E,F), in contrast to observations using the HSP90 inhibitors.




Figure 5. Contractility but not motility regulated via the ROCK pathway. Effects of ROCK inhibitors upon CAF collagen contractility was measured, after which the cell viability was examined by MTS assay. (A) The ROCK inhibitor Y-27632 impaired CAF contractility and showed no cytotoxic effects in an MTS assay (B); (C) The ROCK inhibitor fasudil inhibited CAF contractility with little cytotoxicity (D); In the scratch assay, Y-27632 (E) and fasudil (F) had no effect. (A–D) CAF from $n = 3$ different patients; repeated measures ANOVA; (E,F) CAF from $n = 4$ patients; paired, two-sided t -test. All panels: mean + S.E.M. and asterisks denote the level of significance * for $p < 0.05$, ** for $p < 0.01$ and *** for $p < 0.001$. n.s. = not significant. Incubation times: CGC 48 h, MTS 3 h, WC 24 h.

3. Discussion

In the current study, we used primary prostate cancer CAF cultures and showed functional impairment in contractility and motility following HSP90 inhibition. Furthermore, reconstituted CAF/tumour cell xenografts were smaller after treatment with HSP90 inhibitors *in vivo*, which may be relevant to patient treatment given the translational model system used. Another study has recently identified a novel HSP90 inhibitor of CAF activity in an oral squamous carcinoma model [38], which is consistent with the data presented here. Together, these studies suggest that inhibition of HSP90 action in CAF can reduce tumour growth, and that these effects are likely in addition to direct effects upon tumour cells themselves. Additionally, a recently published study suggested that inhibition of extracellular HSP90 α derived from prostate tumour cells can convert normal prostatic fibroblasts into CAF [22]. Thus, HSP90 inhibitors could interfere with pro-tumourigenic activities in tumour cells themselves, their secreted extracellular HSP90, as well as via intracellular HSP90 in CAF.

Most studies of HSP90 inhibition have focussed upon direct effects in tumour cell lines without consideration of CAF or TME effects [37,39]. Our approach augments these studies as we have studied HSP90 effects on CAF *in vitro* and reconstituted CAF-mediated tumours *in vivo*. We observed that CAF-dependent tumour growth of BPH1 cells was impeded by HSP90 inhibitors *in vivo*. Taken together, these studies imply that HSP90 inhibition not only affects prostate tumour cells directly but also CAF and the interactions between these cell types.

Studies on the presence of reactive stroma in human prostate tumours have demonstrated that stromal histology can predict patient outcome [30]. Heterogeneity within the TME and CAF populations is well documented and there may be co-evolution between CAF or CAF subsets within patient subgroups [40]. Therefore, we speculated that CAF properties may change during disease progression, and examined whether there were changes in contractility in CAF isolated from tumours with low or high Gleason score. There was no overall correlation between Gleason score and contractility, but a selective analysis of the most and least contractile CAF did show an inverse correlation with Gleason score. Similarly, we observed a correlation between patient age and CAF contractility such that the most contractile CAF were found in younger patients and the least contractile CAF were found in older patients. When our most and least contractile CAF were assayed in tumour reconstitution with BPH1 cells *in vivo*, there was a suggestion that the most contractile CAF led to greater tumour size, however this was not statistically significant. We conclude that further investigation with larger numbers of CAF is required to determine if there is a correlation between contractility and pro-tumourigenic activity of CAF.

Treatment of CAF with HSP90 inhibitors is likely to affect several parameters of cell homeostasis as well as secretion of chemokines and growth factors. We chose to examine secreted TGF β , for which both, pro- and anti-tumourigenic effects have been described in the literature [41,42]. HSP90 inhibition with 17-DMAG surprisingly increased TGF β 2 secretion by CAF, with no effect upon TGF β 1 or TGF β 3. The increased secretion of TGF β 2 may be augmented by stroma-specific expression of cathepsin D, as secreted TGF β s are bound to the ECM in a latent, inactivated form [43]. It is conceivable that increased levels of proteases lead to a higher TGF β 2 release via cleavage from extracellular sources or that there is a direct effect upon TGF β 2 synthesis and secretion. This increase in TGF β 2 may exert several effects upon tumour growth *in vivo*, however, we saw no direct effects of TGF β 2 or TGF β 2 inhibition upon CAF contractility. The physiological effect of elevated TGF β 2 on the tumour could potentially result in increased extravasation [41] but which is reduced following HSP90 inhibition.

HSP70 and HSP90 proteins were found to be up-regulated after exposure to HSP90 inhibitors. Heat shock factor protein 1 (HSF1) is an HSP90 client and HSP90 inhibition leads to HSF1 dissociation from HSP90 and subsequent HSF1 activation, which in turn is a transcription factor for HSP90. A recent study suggested dual inhibition of HSF1 and HSP90 for improved tumour reduction [44].

Regarding their mechanism of action, HSP90 inhibitors have pleiotropic effects. In respect to contractility, we suggest that the Rho/ROCK pathway may be active since ROCK inhibitors mimicked the effect of HSP90 inhibitors in the contraction assay. Motility was affected by HSP90 but not by ROCK

inhibitors, suggesting that additional effector pathways were inhibited by radicicol and 17-DMAG. This view is in accordance with a recent study in which HSP90 interaction with its human client proteins was quantified. HSP90 bound 7% of the transcription factors, but 30% of ubiquitin ligases and 60% of kinases investigated [45]. Interestingly, both ROCK and one of its downstream effectors, focal adhesion kinase (FAK), were reported to be weak interaction partners of HSP90 in this study. This might explain why the HSP90 inhibitors showed effects upon motility, but the ROCK inhibitors did not.

Since hundreds of HSP90 clients have been confirmed and identified, it is likely that HSP90 inhibitory effects on CAF and other cells results from combinatorial inhibitory effects on several different pathways. Novel and potentially interesting HSP90 inhibitors have been tested in preclinical cancer studies with focus on the tumour cells but most have not entered clinical trials for prostate cancer yet [38,46–50]. There are clinical trials with results for phase I and II, while phase III trials are ongoing. Compound-specific efficacies and side effects were identified. The compound retaspimycin hydrochloride (IPI-504) was tested in a phase II trial on 19 patients with castration-resistant prostate cancer (CRPC) with little or no efficacy but severe side effects [33]. In contrast, for a phase I clinical trial for 17-DMAG, over 20 patients were enrolled, who suffered different types of solid malignancies, including CRPC, which were partially responsive to treatment. This was a dose escalation study, and doses of <80 mg/m² were well tolerated with tolerable adverse events. Unfortunately, the maximal dose of 106 mg/m² resulted in severe side effects, including death [51].

This suggests that HSP90 inhibitors may be of use in prostate cancer and other malignancies. There is no HSP90 inhibitor that has successfully completed a phase III trial yet or gained market approval, as the compounds were either difficult to synthesise, structurally unstable or too toxic. However, these candidates were based on geldanamycin as original lead compounds and constitute the so-called first generation of HSP90 inhibitors. The 2nd generation of HSP90 inhibitors appear to have less toxicity and are currently under development in clinical trials phase I to III, e.g., ganetispib (Synta) or AUY922 (Novartis) (reviewed in [14,52,53] and references therein).

In summary, our study utilised primary prostate cancer CAF and demonstrated that key characteristics such as contractility and motility can be inhibited by HSP90 inhibition. In a clinically relevant *in vivo* model of prostate cancer composed of BPH1 cells and CAF, the application of HSP90 inhibitors reduced tumour growth, confirming and extending previous findings. Therefore we suggest that HSP90 is a potential target not only in tumour cells but also in CAF as part of the TME.

4. Materials and Methods

4.1. Tissue and Cells

PCa patients undergoing transurethral resection of the prostate (TURP) provided informed written consent for donating tissue, which was approved by the Eastern Multicentre Research Ethics Committee, MREC 02/5/63. The grading of the tumour is contemporary but based on the initial suggestion [54]. Clinical parameters and CAF experimental design are listed in Supplementary Table S1. CAF were grown as described previously and used for experiments at passage numbers 4 and 5, minimising epithelial contamination and senescence, consistent with previously reported studies [1]. BPH1 cells are initiated but non-tumourigenic cells, while WPMY-1 cells are immortalised human prostatic myofibroblasts [55,56].

4.2. Chemicals

Cell culture reagents were from Life Technologies (Paisley, UK), chemicals and small inhibitory compounds from Sigma-Aldrich (Poole, UK or St. Louis, MO, USA). The compound dipalmitoylradicicol was a generous gift, kindly provided by Dr. Akihiro Kitamura (Daiichi Sankyo, Tokyo, Japan). The collagen solution used for 3D-assays was made using a previously published protocol [57].

4.3. Cell Culture Assays

For 3D collagen gel contraction (CGC) assays, CAF were seeded into a collagen lattice at a final concentration of 25,000 cells/mL in 1 mg/mL final collagen concentration in 24 well plates, the suspension (0.5 mL) allowed to gel for 30–45 min at 37 °C, followed by addition of 1 mL medium per well (DMEM with 5% FCS). Gels were dislodged from the walls and bottom of the dish and photographed after 24 and 48 h of incubation with a Leica MZ6 stereo microscope and attached Leica ICA camera (Leica Microsystems, Deerfield, IL, USA). Experiments were performed in triplicate with 1–3 repetitions per CAF population.

Cell viability after CGC was checked with the CellTiter 96[®] AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Southampton, UK). The gels were washed 3× with PBS and then incubated with 300 µL medium and 60 µL reagent for two hours. 120 µL of the gently mixed medium/reagent mixture was transferred into a clean 96 well plate and the absorbance measured on a UV-vis spectrophotometer.

A scratch assay was performed on confluent CAF in 2D in 24 well plates by scratching with a pipette tip two crosses into the cell layer. After gentle washing with PBS, the cells were covered with 1 mL/well DMEM that contained only 1% FCS so as to avoid cell senescence due to serum starvation. Wounds were imaged at 0 and 24 hours with an Axiovert 200M inverted microscope, 5× plan-neofluar objective and an Axiocam MR3, and analyzed the images via Axiovision Software 4.8 (all Zeiss, Jena, Germany) and ImageJ [58]. Quadruplicate measurement per CAF population were performed and several different CAF populations were analysed.

4.4. Multiplex Assays

The methodology of bead-based multiplex assays is similar to ELISA using small beads, which in turn are analysed for their fluorescence via multi-channel flow cytometry. Here, cells were seeded into 24 well plates and the following day treatment was started in 1 mL medium (DMEM, 1% FCS) per well for 24 h. Supernatants were recovered, centrifuged for the removal of debris, and stored at −80 °C until use. The Cells were lysed with RIPA supplemented with protease and phosphatase inhibitors and also kept frozen at −80 °C until use. Aliquots of the lysates were quantified by using the DC Protein Assay kit (BioRad, Hertfordshire, UK) according to manufacturer's instructions. We used the Milliplex Map Kit for measuring secretion of TGFβ1,2,3 (Millipore, Billerica, MA, USA) and the Widescreen BeadPlex Human Heat Shock Protein Panel (Merck, Darmstadt, Germany) on a BioPlex 200 System (BioRad, Hercules, CA, USA) according to manufacturers' instructions.

4.5. In Vivo Studies

All animal experiments were approved by the Vanderbilt IACUC. Young male CB-17/IcrHsd-Prkdc-SCID mice, were purchased from Harlan (Dublin, VA, USA). Recombinant xenografts were made by mixing 1×10^5 BPH1 cells and 2.5×10^5 CAF per graft in collagen solution, allowed to gel, covered with medium and cultured overnight. The following day recombinants were grafted to the subrenal capsule site under isoflurane anaesthesia. Two grafts per kidney per animal were transplanted, as described previously [1]. For each CAF population and dose group, three grafts were transplanted. In addition, mice received a subcutaneous transplant that slowly released testosterone to raise the endogenous levels to those comparable in humans, as described previously [1]. Tumours were allowed to form over eight weeks, and then treated for four weeks with three different doses of dipalmitoyl-radicicol (50, 100 and 200 mg/kg) and 17-DMAG (5, 10 and 20 mg/kg) via intraperitoneal injections of compounds in sesame oil every four days. After 12 weeks in total, the mice were sacrificed, their kidneys resected, grafts cut in half and photographed before processing for histology. Graft dimensions were measured and the resultant tumour volume was calculated using the formula; $\text{volume} = \text{width} \times \text{length} \times \text{depth} \times \pi/6$. This formula represented a conservative approach to evaluate tumour volumes, as it understates the volume of large, invasive

tumours compared with smaller, non-invasive tumours. Resected grafts were fixed in 10% formalin, embedded in paraffin and processed for immunohistochemistry.

4.6. Immunohistochemistry and Staining of Tissue Sections

Human TURP samples and mouse kidneys with grafts attached were fixed in formaldehyde solution, processed and embedded in wax. Details of IHC were described previously [24]. Picrosirius red staining was performed as previously described [28]. The Ki67 evaluation was performed by examining three images per graft using the free application ImmunoRatio for automated image analysis [59].

4.7. Statistics

Statistical analysis performed with GraphPad Prism Software (San Diego, CA, USA) with tests as indicated in the text or figure legends. A $p < 0.05$ was considered statistically significant. p -levels are indicated by asterisks with $p < 0.05$ as *, $p < 0.01$ as ** and $p < 0.001$ as ***. Graphs show the mean plus the S.E.M.

5. Conclusions

Our studies support the hypothesis that HSP90 inhibitors may act upon CAF in addition to direct effects upon tumour epithelia. We demonstrate that HSP90 inhibitors can inhibit CAF contractility and motility in vitro, and that further investigation is warranted.

Supplementary Materials: The following are available online at <http://www.mdpi.com/2072-6694/8/9/77/s1>. Figure S1: Histology of CAF/BPH1 tumours after treatments with HSP90 inhibitors in vivo, Figure S2: Contractility of CAF from patients of different age and Gleason grade, Figure S3: Reconstituted tumour sizes from CAF showing minimal and maximal contractility, Figure S4: Effects of Dorsomorphin upon CAF contractility, Figure S5: Effects of HSP90 inhibitors upon cellular levels of HSP27, Phospho-HSP27, and HSP60, Table S1: Collagen contractility and Gleason grade and patient age, Table S2: Tumour size elicited by most versus least contractile CAF.

Acknowledgments: The authors thank Cathal O. Grace for technical help and Nick Hastie for advice. This work was funded by the Medical Research Council (WBS# 1276.00.003.00004.01), the Prostate Cancer Charity UK (grant 110702 to A.A.T.) (<http://www.prostate-cancer.org.uk>), and National Cancer Institute (grant no. CA151924 to S.W.H.).

Author Contributions: A.H., and A.A.T. conceived the study and experiments, A.H., and O.E.F. performed experiments and analysed data, G.D.S., and A.C.P.R. consented patients, performed surgery and provided patient material, E.K. provided reagents and expertise, S.W.H., and A.A.T. supervised the project and A.H., S.W.H., and A.A.T. wrote the article.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:

CAF	Cancer associated fibroblast
CGC	Collagen gel contraction
GS	Gleason Score
HSP	Heat shock protein
PCa	Prostate cancer
TME	Tumour microenvironment
WC	Wound closure

References

1. Olumi, A.F.; Grossfeld, G.D.; Hayward, S.W.; Carroll, P.R.; Tlsty, T.D.; Cunha, G.R. Carcinoma-associated fibroblasts direct tumour progression of initiated human prostatic epithelium. *Cancer Res.* **1999**, *59*, 5002–5011. [PubMed]

2. Orimo, A.; Gupta, P.B.; SgROI, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L.; Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumour growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell* **2005**, *121*, 335–348. [[CrossRef](#)] [[PubMed](#)]
3. Ao, M.; Franco, O.E.; Park, D.; Raman, D.; Williams, K.; Hayward, S.W. Cross-talk between Paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. *Cancer Res.* **2007**, *67*, 4244–4253. [[CrossRef](#)] [[PubMed](#)]
4. Franco, O.E.; Jiang, M.; Strand, D.W.; Peacock, J.; Fernandez, S.; Jackson, R.S., 2nd; Revelo, M.P.; Bhowmick, N.A.; Hayward, S.W. Altered TGF- β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. *Cancer Res.* **2011**, *71*, 1272–1281. [[CrossRef](#)] [[PubMed](#)]
5. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. *Nat. Rev. Cancer* **2006**, *6*, 392–401. [[CrossRef](#)] [[PubMed](#)]
6. Levental, K.R.; Yu, H.; Kass, L.; Lakins, J.N.; Egeblad, M.; Erler, J.T.; Fong, S.F.; Csiszar, K.; Giaccia, A.; Wenginger, W.; et al. Matrix crosslinking forces tumour progression by enhancing integrin signaling. *Cell* **2009**, *139*, 891–906. [[CrossRef](#)] [[PubMed](#)]
7. Scott, R.W.; Hooper, S.; Crighton, D.; Li, A.; Konig, I.; Munro, J.; Trivier, E.; Wickman, G.; Morin, P.; Croft, D.R.; et al. LIM kinases are required for invasive path generation by tumour and tumour-associated stromal cells. *J. Cell Biol.* **2010**, *191*, 169–185. [[CrossRef](#)] [[PubMed](#)]
8. Gaggioli, C.; Hooper, S.; Hidalgo-Carcedo, C.; Grosse, R.; Marshall, J.F.; Harrington, K.; Sahai, E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nat. Cell Biol.* **2007**, *9*, 1392–1400. [[CrossRef](#)] [[PubMed](#)]
9. Samuel, M.S.; Lopez, J.I.; McGhee, E.J.; Croft, D.R.; Strachan, D.; Timpson, P.; Munro, J.; Schroder, E.; Zhou, J.; Brunton, V.G.; et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and β -catenin activation to induce epidermal hyperplasia and tumour growth. *Cancer Cell* **2011**, *19*, 776–791. [[CrossRef](#)] [[PubMed](#)]
10. Sluka, P.; Davis, I.D. Cell mates: Paracrine and stromal targets for prostate cancer therapy. *Nat. Rev. Urol.* **2013**, *10*, 441–451. [[CrossRef](#)] [[PubMed](#)]
11. Campbell, I.; Polyak, K.; Haviv, I. Clonal mutations in the cancer-associated fibroblasts: The case against genetic coevolution. *Cancer Res.* **2009**, *69*, 6765–6768. [[CrossRef](#)] [[PubMed](#)]
12. Franco, O.E.; Hayward, S.W. Targeting the tumour stroma as a novel therapeutic approach for prostate cancer. *Adv. Pharmacol.* **2012**, *65*, 267–313. [[PubMed](#)]
13. Barrott, J.J.; Haystead, T.A. HSP90, an unlikely ally in the war on cancer. *FEBS J.* **2013**, *280*, 1381–1396. [[CrossRef](#)] [[PubMed](#)]
14. Tatokoro, M.; Koga, F.; Yoshida, S.; Kihara, K. Heat Shock Protein 90 targeting therapy: State of the art and future perspective. *EXCLI J.* **2015**, *14*, 48–58. [[PubMed](#)]
15. Taiyab, A.; Rao, C. HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion. *Biochim. Biophys. Acta* **2011**, *1813*, 213–221. [[CrossRef](#)] [[PubMed](#)]
16. Lang, S.A.; Klein, D.; Moser, C.; Gaumann, A.; Glockzin, G.; Dahlke, M.H.; Dietmaier, W.; Bolder, U.; Schlitt, H.J.; Geissler, E.K.; et al. Inhibition of Heat Shock Protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumour growth and vascularization in vivo. *Mol. Cancer Ther.* **2007**, *6*, 1123–1132. [[CrossRef](#)] [[PubMed](#)]
17. Kaur, G.; Belotti, D.; Burger, A.M.; Fisher-Nielson, K.; Borsotti, P.; Riccardi, E.; Thillainathan, J.; Hollingshead, M.; Sausville, E.A.; Giavazzi, R. Antiangiogenic properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An orally bioavailable Heat Shock Protein 90 modulator. *Clin. Cancer Res.* **2004**, *10*, 4813–4821. [[CrossRef](#)] [[PubMed](#)]
18. Radovanac, K.; Morgner, J.; Schulz, J.N.; Blumbach, K.; Patterson, C.; Geiger, T.; Mann, M.; Krieg, T.; Eckes, B.; Fassler, R.; et al. Stabilization of integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response. *EMBO J.* **2013**, *32*, 1409–1424. [[CrossRef](#)] [[PubMed](#)]
19. Lee, W.J.; Lee, J.H.; Ahn, H.M.; Song, S.Y.; Kim, Y.O.; Lew, D.H.; Yun, C.O. Heat Shock Protein 90 inhibitor decreases collagen synthesis of keloid fibroblasts and attenuates the extracellular matrix on the keloid spheroid model. *Plast. Reconstr. Surg.* **2015**, *136*, 328e–337e. [[CrossRef](#)] [[PubMed](#)]

20. Jung, D.W.; Kim, J.; Che, Z.M.; Oh, E.S.; Kim, G.; Eom, S.H.; Im, S.H.; Ha, H.H.; Chang, Y.T.; Williams, D.R.; et al. A triazine compound S06 inhibits proinvasive crosstalk between carcinoma cells and stromal fibroblasts via binding to Heat Shock Protein 90. *Chem. Biol.* **2011**, *18*, 1581–1590. [[CrossRef](#)] [[PubMed](#)]
21. Hance, M.W.; Dole, K.; Gopal, U.; Bohonowych, J.E.; Jezierska-Drutel, A.; Neumann, C.A.; Liu, H.; Garraway, I.P.; Isaacs, J.S. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. *J. Biol. Chem.* **2012**, *287*, 37732–37744. [[CrossRef](#)] [[PubMed](#)]
22. Bohonowych, J.E.; Hance, M.W.; Nolan, K.D.; Defee, M.; Parsons, C.H.; Isaacs, J.S. Extracellular Hsp90 mediates an NF- κ B dependent inflammatory stromal program: Implications for the prostate tumour microenvironment. *Prostate* **2014**, *74*, 395–407. [[CrossRef](#)] [[PubMed](#)]
23. Whitaker, H.C.; Kote-Jarai, Z.; Ross-Adams, H.; Warren, A.Y.; Burge, J.; George, A.; Bancroft, E.; Jhavar, S.; Leongamornlert, D.; Tymrakiewicz, M.; et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein- β expression in tissue and urine. *PLoS ONE* **2010**, *5*, e13363. [[CrossRef](#)] [[PubMed](#)]
24. Orr, B.; Grace, O.C.; Brown, P.; Riddick, A.C.; Stewart, G.D.; Franco, O.E.; Hayward, S.W.; Thomson, A.A. Reduction of pro-tumourigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1. *Dis. Model. Mech.* **2013**, *6*, 530–536. [[CrossRef](#)] [[PubMed](#)]
25. Kiskowski, M.A.; Jackson, R.S., 2nd; Banerjee, J.; Li, X.; Kang, M.; Iturregui, J.M.; Franco, O.E.; Hayward, S.W.; Bhowmick, N.A. Role for stromal heterogeneity in prostate tumourigenesis. *Cancer Res.* **2011**, *71*, 3459–3470. [[CrossRef](#)] [[PubMed](#)]
26. Sugimoto, H.; Mundel, T.M.; Kieran, M.W.; Kalluri, R. Identification of fibroblast heterogeneity in the tumour microenvironment. *Cancer Biol. Ther.* **2006**, *5*, 1640–1646. [[CrossRef](#)] [[PubMed](#)]
27. Kassen, A.; Sutkowski, D.M.; Ahn, H.; Sensibar, J.A.; Kozlowski, J.M.; Lee, C. Stromal cells of the human prostate: Initial isolation and characterization. *Prostate* **1996**, *28*, 89–97. [[CrossRef](#)]
28. Junqueira, L.C.; Bignolas, G.; Brentani, R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. *Histochem. J.* **1979**, *11*, 447–455. [[CrossRef](#)] [[PubMed](#)]
29. Tlsty, T.D.; Coussens, L.M. Tumour stroma and regulation of cancer development. *Annu. Rev. Pathol.* **2006**, *1*, 119–150. [[CrossRef](#)] [[PubMed](#)]
30. Ayala, G.; Tuxhorn, J.A.; Wheeler, T.M.; Frolov, A.; Scardino, P.T.; Otori, M.; Wheeler, M.; Spitler, J.; Rowley, D.R. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. *Clin. Cancer Res.* **2003**, *9*, 4792–4801. [[PubMed](#)]
31. Oikawa, T.; Onozawa, C.; Kuranuki, S.; Igarashi, Y.; Sato, M.; Ashino, H.; Shimamura, M.; Toi, M.; Kurakata, S. Dipalmitoylation of radicicol results in improved efficacy against tumour growth and angiogenesis in vivo. *Cancer Sci.* **2007**, *98*, 219–225. [[CrossRef](#)] [[PubMed](#)]
32. Floris, G.; Debiec-Rychter, M.; Wozniak, A.; Stefan, C.; Normant, E.; Faa, G.; Machiels, K.; Vanleeuw, U.; Sciot, R.; Schoffski, P. The Heat Shock Protein 90 inhibitor IPI-504 induces KIT degradation, tumour shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumours. *Mol. Cancer Ther.* **2011**, *10*, 1897–1908. [[CrossRef](#)] [[PubMed](#)]
33. Oh, W.K.; Galsky, M.D.; Stadler, W.M.; Srinivas, S.; Chu, F.; Buble, G.; Goddard, J.; Dunbar, J.; Ross, R.W. Multicenter phase II trial of the Heat Shock Protein 90 inhibitor, Retaspimycin Hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. *Urology* **2011**, *78*, 626–630. [[CrossRef](#)] [[PubMed](#)]
34. Vogt, J.; Traynor, R.; Sapkota, G.P. The specificities of small molecule inhibitors of the TGF β s and BMP pathways. *Cell Signal.* **2011**, *23*, 1831–1842. [[CrossRef](#)] [[PubMed](#)]
35. Casey, T.M.; Eneman, J.; Crocker, A.; White, J.; Tessitore, J.; Stanley, M.; Harlow, S.; Bunn, J.Y.; Weaver, D.; Muss, H.; et al. Cancer associated fibroblasts stimulated by transforming growth factor β 1 (TGF- β 1) increase invasion rate of tumour cells: A population study. *Breast Cancer Res. Treat.* **2008**, *110*, 39–49. [[CrossRef](#)] [[PubMed](#)]
36. Peehl, D.M.; Sellers, R.G. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. *Exp. Cell Res.* **1997**, *232*, 208–215. [[CrossRef](#)] [[PubMed](#)]
37. Gerdes, M.J.; Larsen, M.; Dang, T.D.; Ressler, S.J.; Tuxhorn, J.A.; Rowley, D.R. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF- β 1. *Prostate* **2004**, *58*, 299–307. [[CrossRef](#)] [[PubMed](#)]

38. Cohen, S.M.; Mukerji, R.; Samadi, A.K.; Zhang, X.; Zhao, H.; Blagg, B.S.; Cohen, M.S. Novel C-terminal Hsp90 inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. *Ann. Surg. Oncol.* **2012**, *19*, S483–S490. [[CrossRef](#)] [[PubMed](#)]
39. O'Malley, K.J.; Langmann, G.; Ai, J.; Ramos-Garcia, R.; Vessella, R.L.; Wang, Z. Hsp90 Inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumours to castration resistance. *Prostate* **2012**, *72*, 1117–1123. [[CrossRef](#)] [[PubMed](#)]
40. Franco, O.E.; Shaw, A.K.; Strand, D.W.; Hayward, S.W. Cancer associated fibroblasts in cancer pathogenesis. *Semin. Cell Dev. Biol.* **2010**, *21*, 33–39. [[CrossRef](#)] [[PubMed](#)]
41. Wegiel, B.; Evans, S.; Hellsten, R.; Otterbein, L.E.; Bjartell, A.; Persson, J.L. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. *Curr. Cancer Drug Targets* **2010**, *10*, 392–401. [[CrossRef](#)] [[PubMed](#)]
42. Li, H.; Xu, D.; Toh, B.H.; Liu, J.P. TGF- β and cancer: Is Smad3 a repressor of hTERT gene? *Cell Res.* **2006**, *16*, 169–173. [[CrossRef](#)] [[PubMed](#)]
43. Pruitt, F.L.; He, Y.; Franco, O.E.; Jiang, M.; Cates, J.M.; Hayward, S.W. Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium. *Prostate* **2013**, *73*, 476–488. [[CrossRef](#)] [[PubMed](#)]
44. Chen, Y.; Chen, J.; Loo, A.; Jaeger, S.; Bagdasarian, L.; Yu, J.; Chung, F.; Korn, J.; Ruddy, D.; Guo, R.; et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. *Oncotarget* **2013**, *4*, 816–829. [[CrossRef](#)] [[PubMed](#)]
45. Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover, K.D.; Karras, G.I.; Lindquist, S. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. *Cell* **2012**, *150*, 987–1001. [[CrossRef](#)] [[PubMed](#)]
46. Eskew, J.D.; Sadikot, T.; Morales, P.; Duren, A.; Dunwiddie, I.; Swink, M.; Zhang, X.; Hembruff, S.; Donnelly, A.; Rajewski, R.A.; et al. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. *BMC Cancer* **2011**. [[CrossRef](#)] [[PubMed](#)]
47. He, S.; Zhang, C.; Shafi, A.A.; Sequeira, M.; Acquaviva, J.; Friedland, J.C.; Sang, J.; Smith, D.L.; Weigel, N.L.; Wada, Y.; et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. *Int. J. Oncol.* **2013**, *42*, 35–43. [[PubMed](#)]
48. Lin, Z.; Peng, R.; Li, Z.; Wang, Y.; Lu, C.; Shen, Y.; Wang, J.; Shi, G. 17-ABAG, a Novel geldanamycin derivative, inhibits LNCaP-cell proliferation through Heat Shock Protein 90 inhibition. *Int. J. Mol. Med.* **2015**, *36*, 424–432. [[PubMed](#)]
49. Wang, J.; Li, Z.; Lin, Z.; Zhao, B.; Wang, Y.; Peng, R.; Wang, M.; Lu, C.; Shi, G.; Shen, Y. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation. *Cancer Lett.* **2015**, *362*, 83–96. [[CrossRef](#)] [[PubMed](#)]
50. Moses, M.A.; Henry, E.C.; Ricke, W.A.; Gasiewicz, T.A. The Heat Shock Protein 90 inhibitor, (–)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer Progression model. *Cancer Prev. Res.* **2015**, *8*, 249–257. [[CrossRef](#)] [[PubMed](#)]
51. Pacey, S.; Wilson, R.H.; Walton, M.; Eatock, M.M.; Hardcastle, A.; Zetterlund, A.; Arkenau, H.T.; Moreno-Farre, J.; Banerji, U.; Roels, B.; et al. A phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumours. *Clin. Cancer Res.* **2011**, *17*, 1561–1570. [[CrossRef](#)] [[PubMed](#)]
52. Sidera, K.; Patsavoudi, E. HSP90 inhibitors: Current development and potential in cancer therapy. *Recent. Pat. Anticancer Drug Discov.* **2014**, *9*, 1–20. [[CrossRef](#)] [[PubMed](#)]
53. Shrestha, L.; Bolaender, A.; Patel, H.J.; Taldone, T. Heat Shock Protein (HSP) drug discovery and development: Targeting heat shock proteins in disease. *Curr. Top. Med. Chem.* **2016**. [[CrossRef](#)]
54. Gleason, D.F.; Mellinger, G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J. Urol.* **1974**, *111*, 58–64. [[CrossRef](#)]
55. Hayward, S.W.; Dahiya, R.; Cunha, G.R.; Bartek, J.; Deshpande, N.; Narayan, P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. *In Vitro Cell Dev. Biol. Anim.* **1995**, *31*, 14–24. [[CrossRef](#)] [[PubMed](#)]
56. Webber, M.M.; Trakul, N.; Thraves, P.S.; Bello-DeOcampo, D.; Chu, W.W.; Storto, P.D.; Huard, T.K.; Rhim, J.S.; Williams, D.E. A human prostatic stromal myofibroblast cell line WPMY-1: A model for stromal-epithelial interactions in prostatic neoplasia. *Carcinogenesis* **1999**, *20*, 1185–1192. [[CrossRef](#)] [[PubMed](#)]

57. Hallowes, R.C.; Bone, E.J.; Jones, W. A new dimension in the culture of human breast. In *Tissue Culture in Medical Research*; Richards, R.J., Rajan, K.T., Eds.; Pergamon Press: Oxford, UK, 1980; pp. 213–220.
58. Abramoff, M.D.; Magalhaes, P.J.; Ram, S.J. Image processing with ImageJ. *Biophotonics Int.* **2004**, *11*, 36–42.
59. Tuominen, V.J.; Ruotoistenmaki, S.; Viitanen, A.; Jumppanen, M.; Isola, J. ImmunoRatio: A publicly available web application for quantitative image analysis of Estrogen Receptor (ER), Progesterone Receptor (PR), and Ki-67. *Breast Cancer Res.* **2010**. [[CrossRef](#)] [[PubMed](#)]



© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).